The company said net income applicable to common shares for the 3 months ended September 30, 2024 increased primarily because of higher Adjusted NOI from its lab and outpatient medical segments, tied to assets acquired in the Merger, development and redevelopment projects placed in service, and new leasing activity. It also cited a larger gain on sales of outpatient medical buildings.

1. 01

   The company said net income applicable to common shares for the 3 months ended September 30, 2024 increased primarily because of higher Adjusted NOI from its lab and outpatient medical segments, tied to assets acquired in the Merger, development and redevelopment projects placed in service, and new leasing activity. It also cited a larger gain on sales of outpatient medical buildings.

2. 02

   The company cited higher interest expense for the 3 months, primarily due to senior unsecured notes assumed in the Merger totaling $1.25 billion, the $400 million 2028 Term Loan, and mortgage debt of $128 million. It also pointed to borrowings under the 2029 Term Loan, which closed in March 2024.

3. 03

   The company said its material cash requirements related to debt as of September 30, 2024 rose $1.7 billion from December 31, 2023 to $8.6 billion, reflecting debt assumed in the Merger and the $750 million 2029 Term Loan, among other items. It said a decrease of $720 million in commercial paper program balances partially offset the increase.

4. 04

   Net cash provided by operating activities for the 9 months ended September 30, 2024 rose $62 million from the prior-year period, the company said. It cited higher Adjusted NOI from assets acquired in the Merger and annual rent escalations as drivers. It said higher merger-related costs and interest payments partially offset the increase.

Key figures

Quarter ended September 30, 2024

Revenue

$700M

Net income

$86M

EPS

$0.12

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.